Registration Dossier

Administrative data

Description of key information

Repeated dose toxicity - oral: In a combined 28-day repeated dose toxicity study with the reproduction/ developmental toxicity screening test, the test substance was administered daily to rats up to a dose level of 1000 mg/kg body weight/day (OECD 422; Mounier, 2017). The NOAEL is established to be at least 1000 mg/kg. Based on the available data and according to the criteria of the CLP Regulation, the test item is therfore not classified as STOT RE according to the CLP Regulation.

Repeated dose toxicity - inhalation: A key study is available for the oral route of exposure. According to the REACH Regulation, only one route of exposure should be tested for repeated dose toxicity (column 2, annex VIII, section 8.6.1). Therefore, it is not necessary to perform a repeated dose toxicity study via the inhalation route of exposure.

Repeated dose toxicity - dermal: A key study is available for the oral route of exposure. According to the REACH Regulation, only one route of exposure should be tested for repeated dose toxicity (column 2, annex VIII, section 8.6.1). Therefore, it is not necessary to perform a repeated dose toxicity study via the dermal route of exposure.

Key value for chemical safety assessment

Repeated dose toxicity: via oral route - systemic effects

Link to relevant study records
Reference
Endpoint:
short-term repeated dose toxicity: oral
Type of information:
experimental study
Adequacy of study:
key study
Study period:
2016-09-22 to 2016-12-27
Reliability:
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
guideline study
Qualifier:
according to
Guideline:
OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
Deviations:
no
Qualifier:
according to
Guideline:
other: EPA OPPTS 870.3650, Combined Repeated Dose Toxicity Study with the Reproduction/Developmental Toxicity Screening Test
Deviations:
no
Qualifier:
equivalent or similar to
Guideline:
EU Method B.7 (Repeated Dose (28 Days) Toxicity (Oral))
Deviations:
no
Qualifier:
equivalent or similar to
Guideline:
OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity in Rodents)
Deviations:
no
Qualifier:
equivalent or similar to
Guideline:
other: OECD 421( Reproduction/Developmental Toxicity Screening Test)
Deviations:
no
Qualifier:
equivalent or similar to
Guideline:
other: EPA OPPTS 870.3550 (Reproduction/Developmental Toxicity Screening Test)
Deviations:
no
Qualifier:
equivalent or similar to
Guideline:
other: EPA OPPTS 870.3050 (Repeated dose 28-day oral toxicity study in rodents)
Deviations:
no
Principles of method if other than guideline:
No testing guidelines were applicable for the pilot phase, as this part of the study was intended for dose level selection purposes only.
GLP compliance:
yes (incl. certificate)
Limit test:
no
Specific details on test material used for the study:
SOURCE OF TEST MATERIAL
- Source and lot/batch No.of test material: I16CB1581
- Expiration date of the lot/batch: 2019-04-04 (retest date).

STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: At room temperature (+15 to +25 °C).
- Stability under test conditions: Stability of the test item under test conditions was demonstrated in the method validation study (study AB21450).
- Solubility and stability of the test substance in the solvent/vehicle: Stability of formulations over 6 hours at room temperature and 15 days refrigerated at concentration of 1 to 200 mg/mL based on results of stability study no. AB21450.

FORM AS APPLIED IN THE TEST: suspension

OTHER SPECIFICS: No correction factor was applied.
Species:
rat
Strain:
Wistar
Remarks:
Crl:WI(Han)
Details on species / strain selection:
This species and strain of rat has been recognized as appropriate for general and reproduction toxicity studies. Charles River Den Bosch has general and reproduction/developmental historical data in this species from the same strain and source. This animal model has been proven to be susceptible to the effects of reproductive toxicants.
Sex:
male/female
Details on test animals and environmental conditions:
TEST ANIMALS
- Source: Charles River Laboratories France, Domaine des Oncins, 69210 Saint-Germain-Nuelles, France.
- Females (if applicable) nulliparous and non-pregnant: yes
- Age at study initiation: males approx. 9 weeks (at start F0-treatment); females approx. 9 weeks (at start pretest) and approx. 11 weeks (at start F0-treatment).
- Weight at study initiation: 237.9 - 258.7 g (males, day -5), 191.1 - 236.9 g (females, day 1)
- Fasting period before study: No
- Housing:
Pretest: Animals were housed in groups of 5 sex/cage.
Pre-mating: Animals were housed in groups of 5 sex/cage.
Mating: Males and females were cohabitated on a 1:1 basis.
Post-mating: Males were housed in their home cage with a maximum of 5 animals/cage. Females were individually housed.
Lactation: Pups were housed with the dam.
- Diet (e.g. ad libitum): Free access to pelleted complete rodent diet
- Water (e.g. ad libitum): Free access to softened and filtered (0.2 μm) mains drinking water,
- Acclimation period: 7 days prior to start of pretest (females) or treatment (males).

ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19 to 25 °C
- Humidity (%): >35 %
- Air changes (per hr): at least 10 room air changes/hour
- Photoperiod (hrs dark / hrs light): 12-hour light/12-hour dark cycle

IN-LIFE DATES:
From: 2016-10-11 (start pretest period females), 2016-10-25 (start treatment males) TO: 2016-11-25 (necropsy males), 2016-12-27 (necropsy females)
Route of administration:
oral: gavage
Details on route of administration:
Method: Oral gavage, using a plastic cannula
Frequency: Once daily for 7 days per week, approximately the same time each day with a maximum of less than 5 hours difference between the earliest and latest dose.
Vehicle:
propylene glycol
Remarks:
density 1.036
Details on oral exposure:
PREPARATION OF DOSING SOLUTIONS:
Formulations (w/v) were prepared weekly (based on stability study no. AB21450) and were homogenized to a visually acceptable level. No adjustment was made for specific gravity/density of the test item, vehicle and/or formulation. A correction was made for the purity/composition of the test item. A correction factor of 1 was used.

VEHICLE
- Justification for use and choice of vehicle (if other than water): Based on trial formulations performed at Charles River Lyon.
- Concentration in vehicle: 0, 22, 66, 200 mg/mL
- Amount of vehicle (if gavage): 5 mL/kg body weight. Actual dose volumes were calculated according to the latest body weight.
- Lot/batch no. (if required): no data
- Purity: no data
Analytical verification of doses or concentrations:
yes
Details on analytical verification of doses or concentrations:
Analyses were conducted on a single occasion on formulations used on the first day of treatment during the main phase (25 October 2016), according to a validated method (Test Facility Study no. AB21450). Three sets of duplicate samples (2 x 1 g) were collected. Two sets of duplicate samples were stored in a refrigerator (+2 to +8 °C) as reserve samples.
Once analytical results were approved in the raw data by the Principal Scientist for analytical chemistry, the reserve samples were destroyed.
Samples of formulations were analyzed for homogeneity (highest and lowest concentrations) and accuracy of preparation (all concentrations).
In addition to the criteria mentioned in the validated analytical method, each calibration curve was accepted if the average of the retention times and response factors of the data points used to construct the calibration line were within a range of ±10 % compared to those obtained during the method validation.
The accuracy of preparation was considered acceptable if the mean measured concentrations were 85-115 % of the target concentration for suspensions. Homogeneity was demonstrated if the coefficient of variation was ≤10 %.
Stability of formulations over 6 hours at room temperature and 15 days refrigerated under normal laboratory light conditions (concentration range 1-200 mg/mL) was confirmed as part of the analytical method development and validation study (Test Facility Study no. AB21450).
Duration of treatment / exposure:
Males 31 days
Females that delivered: 51-63 days
Females which failed to deliver: 39-41 days.
Pups were not dosed directly but were potentially exposed to the test item in utero, via maternal milk or from exposure to maternal urine/faeces.
Frequency of treatment:
Once daily for 7 days per week, approximately the same time each day with a maximum of less than 5 hours difference between the earliest and latest dose.
Dose / conc.:
0 mg/kg bw/day (nominal)
Remarks:
Group 1 (Control)
Dose / conc.:
110 mg/kg bw/day (nominal)
Remarks:
Group 2
Dose / conc.:
330 mg/kg bw/day (nominal)
Remarks:
Group 3
Dose / conc.:
1 000 mg/kg bw/day (nominal)
Remarks:
Group 4
No. of animals per sex per dose:
10 animals/sex/dose level
Control animals:
yes, concurrent vehicle
Details on study design:
- Dose selection rationale: During the DRF phase, oral (gavage) administration of JNJ-39453349-AAA (T003066) to the female Han Wistar rat for 10 days at doses of 500 and 1000 mg/kg/day was not associated with any systemic effects. For the main phase, dose levels of 110, 330 and 1000 mg/kg/day were selected.
- Rationale for animal assignment (if not random): randomized
Positive control:
no
Observations and examinations performed and frequency:
CAGE SIDE OBSERVATIONS: Yes
- Time schedule: at least twice daily (at the beginning and at the end of the working day, including weekends and public holidays)

DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: before and at least once after dosing (between 1 and 3 hours), from start of treatment onwards up to the day prior to necropsy. Animals were observed once daily on non-treatment days. A full clinical examination was performed on each weighing day. The time of onset, grade (where applicable) and duration of any observed sign was recorded.

BODY WEIGHT: Yes
- Time schedule: Males and females were weighed on the first day of treatment and weekly thereafter. Mated females were weighed on Days 0, 4, 7, 11, 14, 17 and 20 post-coitum and during lactation on PND 1, 4, 7 and 13. Body weight and calculated body weight gain were reported.

FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study): yes
- Time schedule: Weekly, except for males and females which were housed together for mating and for females without evidence of mating. Food consumption of mated females was measured on Days 0, 4, 7, 11, 14, 17 and 20 post-coitum and on PND 1, 4, 7 and 13. Both absolute food consumption and food consumption relative to body weight were reported.
- compound intake calculated as time-weighed averages from the consumption and body weight gain data: not applicable

WATER CONSUMPTION: No
- Subjective appraisal was maintained during the study, but no quantitative investigation was introduced as no treatment related effect was suspected.

HAEMATOLOGY: Yes
- Blood samples were collected at the end of the treatment period on the day of the scheduled necropsy from the selected 5 animals/sex/group under anaesthesia using isoflurane. The animals were deprived of food overnight (with a maximum of 24 hours) before blood sampling, but water was available. Blood samples were drawn from the retro-orbital sinus and collected into tubes with K2-EDTA for hematology parameters, and with citrate for clotting tests
- parameters assessed: white blood cells, differential white blood cell count (neutrophils, lymphocytes, monocytes, eosinophils, basophils, large unstained cells), red blood cell count, reticulocytes count, red blood cell distribution width, haemoglobin, haematocrit, mean corpuscular volume, mean corpuscular haemoglobin, mean corpuscular haemoglobin concentration, platelet count, prothrombin time, activated partial thromboplastin time

CLINICAL CHEMISTRY: Yes
- Blood samples were collected at the end of the treatment period on the day of the scheduled necropsy from the selected 5 animals/sex/group under anaesthesia using isoflurane. The animals were deprived of food overnight (with a maximum of 24 hours) before blood sampling, but water was available. Blood samples were drawn from the retro-orbital sinus and collected into tubes with Li-heparin for clinical biochemistry parameters. An additional blood sample was collected into serum tubes for determination of bile acids.
- parameters checked: alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, total protein, albumin, total bilirubin, bile acids, urea, creatinine, glucose, cholesterol, sodium, potassium, chloride, calcium, inorganic phosphate,
- thyroid hormone analysis: Blood sampling at the end of study from all animals at planned necropsy; this included females on day 14 of lactation, all non-mated females, non-pregnant females and all males after 4 weeks of treatment (including all males that failed to sire). No samples were collected from any females that were sacrificed in extremis or found dead and females with total litter loss. Blood samples were collected, under anesthesia using isoflurane. The animals were deprived of food overnight (less than 24 hours) before blood sampling, but water was available. Blood samples (0.9 mL, target volume) were drawn from the retro-orbital sinus and collected into tubes without anticoagulant. After clotting and centrifugation, serum was used as:
- males 1 aliquot of 150 µL serum was used for measurement of T4 and the remaining volume of serum was kept for possible future measurement of thyroid-stimulating hormone (TSH)
- females: the serum was kept for possible future measurement of T4 and/or TSH

FUNCTIONAL OBSERVATIONS
- Time schedule: The selected males were tested once during week 5 of treatment and the selected females were teted once during the last week of lactation, on PND 13. These tests were performed approx 1.5 hour and 3 hours for females and males, respectively, after observation for clinical signs.
- Dose groups that were examined: selected 5 animals/sex/group
- battery of functions tested: hearing ability, pupillary reflex, static righting reflex, fore- and hind-limb grip strength recorded as the mean of 3 measurements per animal, locomotor activity in an open field test
- parameters: hearing ability, pupillary reflex, static righting reflex, fore and hind-limb grip strength recorded as mean of three measurements per animal, locomotor activity
Sacrifice and pathology:
SACRIFICE
Adult animals were deprived of food overnight (less than 24 hours) before scheduled necropsy, but water was available.
The 5 selected males and females were deeply anaesthetized using isoflurane (AErrane, Baxter) and subsequently exsanguinated.
Other adult animals surviving to the end of the observation period, any moribund adult animals and females with total litter death were killed by carbon dioxide inhalation and exsanguination then necropsied. Any found dead adult animals were also submitted to necropsy procedures.
Necropsy was conducted according to the following schedule:
- Males: following completion of the mating period (after 31 days of dose administration).
- Females which delivered: on PND 14.
- Females which failed to deliver: on post-coitum Day 26 (females with evidence of mating) or 25 days after the last day of the mating period (female without evidence of mating).
- Females with total litter loss: within 24 hours of litter loss.
- Spontaneous deaths: as soon as possible after death and always within 24 hours.
- Euthanized in extremis: when pain, distress or discomfort was considered not transient in nature or was likely to become more severe.

GROSS PATHOLOGY: Yes
- After sacrifice, all animals were subjected to a full post mortem necropsy, with special attention being paid to the reproductive organs. Descriptions of all macroscopic abnormalities were recorded.
- Samples of the following tissues and organs were collected and fixed in 10% buffered formalin, for selected 5 animals/sex/group and all animals that died spontaneously or were killed in extremis: Adrenal glands (M/F), (Aorta) (M/F), Brain - cerebellum, mid-brain, cortex (7 levels) (M/F), Caecum (M/F), Cervix (F), Clitoral gland (F), Colon (M/F), Coagulation gland (M), (Cowper’s gland) (M), Duodenum (M/F), Epididymides (M), Eyes (with optic nerve (if detectable) and Harderian gland) (M/F), Mammary gland area (M/F), Femur including joint (M/F), (Glans penis) (M), (Levator ani plus bulbocavernosus muscle complex (LABC)) (M), Heart (M/F), Ileum (M/ F), Jejunum (M/F), Kidneys (M/F), (Lacrimal gland, exorbital) (M/F), (Larynx) (M/F), Liver (M/F), Lung , infused with formalin (M/F), Liver (M/F), (Nasopharynx) (M/F) (Esophagus) (M/F), Ovaries (F), (Pancreas) (M/F), Peyer's patches [jejunum, ileum] if detectable (M/F), Pituitary gland (M/F), Preputial gland (M), Prostate gland (M), Rectum (M/F), (Salivary glands - mandibular, sublingual) (M/F), Sciatic nerve (M/F), Seminal vesicles (F), Skeletal muscle (M/F), (Skin) (M/F), Spinal cord -cervical, midthoracic, lumbar (M/F), Spleen (M/F), Sternum with bone marrow (M/F), Stomach (M/F), Testes ( M), Thymus (M/F), Thyroid including parathyroid if detectable (M/F), (Tongue) (M/F), Trachea (M/F), Urinary bladder (M/F), Uterus (F), Vagina (F), All gross lesions (M/F)
Tissues/organs mentioned in parentheses were not examined by the pathologist, since no signs of toxicity were noted at macroscopic examination.
-Samples of the following tissues and organs of all remaining animals, males that fail to sire and females which fail to deliver, were collected and fixed in 10% buffered formalin: Cervix (F), Clitoral gland (F), coagulation gland (M), Cowper’s glands (M), Epididymides (M), Glans penis (M), Levat or ani plus bulbocavernosus muscle complex (LABC) (M), Mammary gland area (M/F), Ovaries (F), Preputial gland (M), Prostate gland (M), Seminal vesicles (M), Testes (M), Thyroid including pa rathyroid if detectable (M/F), Uterus (F), Vagina (F), All gross lesions (M/F)

HISTOPATHOLOGY: Yes
- All organ and tissue samples were processed, embedded and cut at a thickness of 2-4 micrometers. These slides were stained with haematoxylin and eosin. The additional slides of the testes (to exam
ine staging of spermatogenesis) were stained with PAS/haematoxylin.
- The following slides were examined by a pathologist: The preserved organs and tissues of the selected 5 animals/sex of Groups 1 and 4; Additional slides of the testes of the selected 5 males
of Groups 1 and 4 and of all males that failed to sire to examine staging of spermatogenesis; The preserved organs and tissues of one female at 1000 mg/kg (no. 72) that was euthanized in extremis;
The mammary gland of one female at 100 mg/kg (no. 54) with total litter loss; All gross lesions of all animals (all dose groups); Thyroid gland of all selected 5 animals of Groups 2 and 3 (males and
females), based on (possible) treatment-related changes in this organ in Group 4; The reproductive organs of all males that failed to sire and all females that failed to deliver healthy pups.
- All abnormalities were described and included in the study report.
Other examinations:
ORGAN WEIGHT
- Absolute organ weights and organ to body weight ratios were reported
- The following organ weights and terminal body weight were recorded from the selected 5 animals/sex/ group on the scheduled day of necropsy: Adrenal glands, Brain, Cowper’s glands, Epididymides, Glans penis, Heart, Kidneys, Levator ani plus, bulbocavernosus muscle complex (LABC), Liver, Ovaries, Prostate, Seminal vesicles including coagulating glands, Spleen, Testes, Thymus, Thyroid, Uterus (including cervix)
- The following organ weights and terminal body weight were recorded from all remaining animals on the scheduled day of necropsy: Cowper’s glands, Epididymides, Glans penis, Levator ani plus bulbocavern osus muscle complex (LABC), Testes, Thyroid
Statistics:
Statistical analyses were performed by the Provantis data acquisition system, where appropriate, as follows:
The best transformation for the data (none, log or rank) was determined depending upon
- the kurtosis of the data
- the probability of the Bartlett's test for homogeneity of the variances and
- an assessment of whether the size of the groups were approximately equal or not.
Non- or log-transformed data were analysed by parametric methods.
Rank transformed data were analysed using non-parametric methods.
Data were then analysed to test for a dose-related trend to detect the lowest dose at which there was a significant effect, based on the Williams test for parametric data or the Shirley's test for non-parametric data.
Homogeneity of means was assessed by analysis of variances (ANOVA) for parametric data or Kruskal-Wallis test for non parametric data.
If no trend was found and means were not homogeneous, the data were analysed by parametric or non-parametric Dunnett's test to look for significant differences from the control group.
Selected incidence data were analysed using the Provantis data acquisition system and/or a SAS software package. A chi2 test was used for all groups followed by Fisher’s two-tailed test with Bonferroni correction for each treated group versus the control if the chi2 was significant.
The locomotor activity in an open field and the oestrous cycle, pre-coital interval and anogenital distance data were analysed using a SAS software package. Levene’s test was used to test the equality of variance across groups and Shapiro-Wilk's test was used to assess the normality of the data distribution in each group. Data with homogenous variances and normal distribution in all groups were analysed using ANOVA followed by Dunnett’s test. Data showing non-homogenous variances or a non-normal distribution in at least one group were analysed using Kruskal-Wallis test followed by the Wilcoxon's rank sum test.
Clinical signs:
effects observed, non-treatment-related
Description (incidence and severity):
There were no test item-related clinical changes in any group.
One male (no. 166) from Day 25 until the end treatment and one female (no.153) from Day 20 to Day 22 had abnormal breathing. This isolated finding was considered incidental. Incidental findings that were noted included localised hairloss, purple area(s) on the tail, bent tail, sore(s) or scab(s), occasionally noted for both sexes in all groups. These findings occurred within the range of background findings to be expected for rats of this age and strain which are housed and treated under the conditions in the study.
Mortality:
mortality observed, non-treatment-related
Description (incidence):
No mortality occurred during the study period that was considered to be related to treatment with the test item. There were 2, 0, 0 and 3 unscheduled deaths in the control, 110, 330 and 1000 mg/kg/day groups, respectively. None of them were considered test item-related.
Female no. 180 given 1000 mg/kg/day was found dead before dosing on Day 6 of treatment. No clinical signs were noted for this female. Although pale foci were seen in the kidneys and lungs, which also had dark lobes, only moderate diffuse congestion was seen histologically and no changes could account for the death of this animal.
Female no. 178 in the same group was found dead on gestation Day 20 (G20), 14 implantations sites were observed at the autopsy. This female lost 14g between G14 and G17. The most significant macroscopic findings were pale raised areas on the left kidney, which correlated with slight bilateral purulent ascending pyelonephritis. The ascending pyelonephritis was associated with marked purulent cystitis, which was considered to be the cause of death. Other macroscopic findings included, distension of the stomach with fluid and several dark foci on the glandular mucosa, which correlated histologically with slight focal erosions and dark foci on the lungs, which correlated histologically with moderate diffuse congestion. Other microscopic changes included, minimal periportal vacuolation in the liver and slight increased cellularity of the bone marrow, which was considered a likely consequence of the higher recruitment of inflammatory cells in the urinary tract.
Control female no. 118 was euthanized for ethical reasons after showing severe clinical signs on treatment Day 6. These included decreased activity, laboured breathing, pilorection and cold to the touch. There were no macroscopic or histological changes that could account for the moribund status of the animal.
Female nos. 114 and 174 in the control and 1000 mg/kg/day groups, respectively, were euthanized on L0 and L1, respectively, after the death of their entire litter.
Female no. 114 had abnormal vocalization, decreased activity and marked piloerection. These observations occurred before delivery. No macroscopic or histological findings were noted for this female.
Female no.174 did not show any clinical signs or difficulty to litter prior the death of her entire litter. In addition, no macroscopic or histological findings were noted. This premature sacrifice was therefore considered incidental.
Body weight and weight changes:
effects observed, non-treatment-related
Description (incidence and severity):
Males: Mean body weights and body weight gain of treated males remained in the same range as controls over the pre-mating treatment period. Non-dose-related minor differences in mean body weight gain were observed but the magnitude of the changes was similar to the pre-treatment differences. These were therefore considered incidental.
Females: Body weights and body weight gains were not obviously affected by treatment for females during pre-mating or lactation periods. During the gestation period, there was a lower, though not statistically significant mean body weight gain in treated than in control females (i.e. 120.6, 126.8 and 114.6g in the 110, 330 and 1000 mg/kg/day groups, respectively, versus 132.5g for controls). Mean body weights were slightly lower in all treated females than in controls at the end of the gestation period. However, differences in mean body weights were already present on Gestation Day 0. Since this change was not dose related and was not associated with any effect on food consumption, it was not considered as toxicologically relevant.
Food consumption and compound intake (if feeding study):
no effects observed
Description (incidence and severity):
Males: The mean food consumption for males in the treated groups between Day 1 and Day 15 of the premating period was comparable with, or superior to that in the control.
Females: There was no treatment related effect on mean food consumption during the premating, gestation or lactation periods at any dose level.
Food efficiency:
not examined
Water consumption and compound intake (if drinking water study):
not examined
Ophthalmological findings:
not examined
Haematological findings:
effects observed, non-treatment-related
Description (incidence and severity):
There were no differences noted in haematological parameters between control and treated rats that were considered to be related to treatment with the test item. Minor statistically significant changes arising between control and treated animals in white blood cell or platelet counts (i.e. slightly increased total white blood cell count including all subsets in males or increased platelet count in females) were considered not to be toxicologically relevant as they were of low magnitude and remained within the range considered normal for rats of this age and strain.
Clinical biochemistry findings:
effects observed, non-treatment-related
Description (incidence and severity):
No toxicologically relevant changes occurred in clinical biochemistry parameters of treated rats.
Any statistically significant changes arising between control and treated animals were not considered to be toxicologically significant as they occurred either in the absence of a treatment-related distribution, were of low magnitude or remained closed or within the range considered normal for rats of this age and strain.
No statistical differences in total T4 levels were noted between control and treated F0 males.
Urinalysis findings:
not examined
Behaviour (functional findings):
no effects observed
Description (incidence and severity):
No toxicologically relevant effects on hearing ability, pupillary reflex, static righting reflex grip strength and open field test were observed.
Immunological findings:
not examined
Organ weight findings including organ / body weight ratios:
effects observed, non-treatment-related
Description (incidence and severity):
There were no test item-related alterations in organ weights. Mean relative kidney weights were slightly higher at all doses, without dose relationship, by up to 17 % in the group given 330 mg/kg/day. Because of the low magnitude of this change and its lack of histological correlate, it was considered unlikely to be treatment-related. All other organ weight variations were also considered to be incidental.
Gross pathological findings:
effects observed, non-treatment-related
Description (incidence and severity):
There were no observations that were considered to be associated with administration of the test item. All findings were considered to be incidental.
Neuropathological findings:
not examined
Histopathological findings: non-neoplastic:
effects observed, non-treatment-related
Description (incidence and severity):
Hypertrophy of the zona glomerulosa of the adrenal glands was seen in two females (minimal or slight) and in one male (minimal) given 1000 mg/kg/day. In the absence of clinical disease, adrenal weight changes, clinical chemistry, in particular electrolyte changes, this finding was not considered to be of any toxicological significance and might reflect normal background physiological variations in the appearance of this zone of the cortex. In addition, as the outermost zone, it is prone to handling artefacts. There was considered to be no test item-related alteration in the prevalence, severity, or histologic character of the remaining histologic changes, which were considered to be incidental findings.
Histopathological findings: neoplastic:
not examined
Other effects:
not examined
Details on results:
Parental results:
No treatment-related changes were noted in any of the parental parameters investigated in this study (i.e. clinical appearance, functional observations, body weight, food consumption, clinical laboratory investigations, macroscopic examination or organ weights, and microscopic examination). Minimal hypertrophy of the zona glomerulosa of the adrenal glands was seen in a few animals at 1000 mg/kg/day. In the absence of clinical disease, adrenal weight changes, clinical chemistry, in particular electrolyte changes, this finding was not considered to be of any toxicological significance and might reflect normal background physiological variations in the appearance of this zone of the cortex. In addition, as the outermost zone, it is prone to handling artefacts.
Key result
Dose descriptor:
NOAEL
Effect level:
>= 1 000 mg/kg bw/day (nominal)
Based on:
test mat.
Sex:
male/female
Remarks on result:
not determinable due to absence of adverse toxic effects
Key result
Critical effects observed:
no

Analysis of dose preparations

All formulations at 22, 66 and 200 mg/mL of test substance in vehicle (propylene glycol), including the vehicle, used on the first day of treatment of the main study, were in agreement with acceptance criteria. The formulations at 22 and 200 mg/mL were homogenous. The deviations from the nominal concentrations ranged from -2.0% to -0.8% , and the RSD was <=0.6%.

No significant amount of test item was detected in the vehicle sample.

Conclusions:
In conclusion, treatment with JNJ-39453349-AAA (T003066) by oral gavage in male and female Wistar Han rats at dose levels of 110, 330 and 1000 mg/kg revealed no adverse toxicity at any dose level.
Based on these results, the No Observed Adverse Effect Level (NOAEL) was concluded to be of at least 1000 mg/kg. Therefore, the substance is not classified as a repeated dose toxicant (STOT RE) according to the CLP Regulation.
Endpoint conclusion
Endpoint conclusion:
no adverse effect observed
Dose descriptor:
NOAEL
1 000 mg/kg bw/day
Study duration:
subacute
Species:
rat

Repeated dose toxicity: inhalation - systemic effects

Link to relevant study records
Reference
Endpoint:
short-term repeated dose toxicity: inhalation
Data waiving:
study scientifically not necessary / other information available
Justification for data waiving:
other:
Endpoint conclusion
Endpoint conclusion:
no study available

Repeated dose toxicity: inhalation - local effects

Link to relevant study records
Reference
Endpoint:
short-term repeated dose toxicity: inhalation
Data waiving:
study scientifically not necessary / other information available
Justification for data waiving:
other:
Endpoint conclusion
Endpoint conclusion:
no study available

Repeated dose toxicity: dermal - systemic effects

Link to relevant study records
Reference
Endpoint:
short-term repeated dose toxicity: dermal
Data waiving:
study scientifically not necessary / other information available
Justification for data waiving:
other:
Endpoint conclusion
Endpoint conclusion:
no study available

Repeated dose toxicity: dermal - local effects

Link to relevant study records
Reference
Endpoint:
short-term repeated dose toxicity: dermal
Data waiving:
study scientifically not necessary / other information available
Justification for data waiving:
other:
Endpoint conclusion
Endpoint conclusion:
no study available

Additional information

Repeated dose toxicity: oral

A combined repeated dose toxicity study with the reproduction/developmental toxicity screening test was performed in rats, in which male and female rats were exposed to 0 (vehicle), 110, 330, and 1000 mg/kg bw/day via gavage (OECD 422; Mounier R., 2017).

The vehicle used was propylene glycol and the test solutions were prepared weekly.

No treatment-related changes were noted in any of the parental parameters investigated in the study (i.e. clinical appearance, functional observations, body weight, food consumption, clinical laboratory investigations, macroscopic examination or organ weights, and microscopic examination). Minimal hypertrophy of the zona glomerulosa of the adrenal glands was seen in a few animals at 1000 mg/kg/day. In the absence of clinical disease, adrenal weight changes, clinical chemistry, in particular electrolyte changes, this finding was not considered to be of any toxicological significance and might reflect normal background physiological variations in the appearance of this zone of the cortex. In addition, as the outermost zone, it is prone to handling artefacts.

Based on these results, the NOAEL was concluded to be at least 1000 mg/kg bw/day.

Repeated dose toxicity: inhalation

A key study is available for the oral route of exposure. According to the REACH Regulation, only one route of exposure should be tested for repeated dose toxicity (column 2, annex VIII, section 8.6.1). Therefore, it is not necessary to perform a repeated dose toxicity study via the inhalation route of exposure.

Repeated dose toxicity: dermal

A key study is available for the oral route of exposure. According to the REACH Regulation, only one route of exposure should be tested for repeated dose toxicity (column 2, annex VIII, section 8.6.1).Therefore, it is not necessary to perform a repeated dose toxicity study via the dermal route of exposure.

Justification for classification or non-classification

Based on the available data and according to the criteria of the CLP Regulation, T003066 should be not be classified as STOT RE via the oral route.